We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at ...

Regulus Therapeutics (NASDAQ:RGLS – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Canaccord Genuity Group in a research note issued on Monday,Benzinga reports. They ...

Regulus Therapeutics Inc.’s RGLS share price has surged by 11.28%, which has investors questioning if this is right time to ...

RGLS opened at $1.48 on Friday. Regulus Therapeutics has a 1 year low of $0.83 and a 1 year high of $3.00. The company has a market capitalization of $96.94 million, a price-to-earnings ratio of ...

Regulus Therapeutics Inc ( ($RGLS) ) has released its Q4 earnings. Here is a breakdown of the information Regulus Therapeutics Inc presented to ...

As at December 2024, Regulus Therapeutics had cash of US$76m and no debt. Looking at the last year, the company burnt through US$42m. That means it had a cash runway of around 22 months as of December ...

Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Regulus Therapeutics Inc. (RGLS) on Thursday reported a loss of $12.8 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Regulus Therapeutics Inc. (RGLS) on Thursday reported a loss of $12.8 million in its fourth quarter. On a per-share basis, the San Diego-based company said it ...